As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...

Dunkirk’s state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...

DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...

A monumental achievement for ImmunityBio, Inc., occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. Earlier this week, the Food and Drug ...

ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

ImmunityBio has secured final local approval to restart its long-delayed Dunkirk, New York manufacturing facility, set to become a key U.S. hub for its cancer immunotherapy Anktiva. The project ...

Add Yahoo as a preferred source to see more of our stories on Google. The stalled Dunkirk pharmaceutical project is moving ahead with a new lease for ImmunityBio and tighter controls. John Travolta ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min With a deficit of $2.5 billion ...

As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...